CARGO Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
CARGO Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Radhakrishnan Anup
CARGO Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Samsara BioCapital, L.P.(9.6%),Samsara BioCapital GP, LLC(9.6%), etc.
CARGO Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(5.8%)
CARGO Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-T. ROWE PRICE ASSOCIATES, INC.(5.9%)
CARGO Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RTW Investments, LP(9.99%),Roderick Wong, M.D.(9.99%)
CARGO Therapeutics | 424B3: Prospectus
CARGO Therapeutics | 10-Q: Q3 2024 Earnings Report
CARGO Therapeutics | 8-K: CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
CARGO Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.5%)
CARGO Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.5%)
CARGO Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Red Tree Venture Fund, L.P.(4.6%),Red Tree GP, LLC(4.6%), etc.
CARGO Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Chapman Gina
CARGO Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Radhakrishnan Anup
CARGO Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
CARGO Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
CARGO Therapeutics | 424B3: Prospectus
CARGO Therapeutics | 10-Q: Q2 2024 Earnings Report
CARGO Therapeutics | 8-K: CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
CARGO Therapeutics | 8-K: Current report